IMCR vs TSHA: stock comparison and AI forecast
Immunocore Holdings Plc (IMCR) and Taysha Gene Therapies, Inc. (TSHA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IMCR Immunocore Holdings Plc
- Market Cap
- $1.55B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
TSHA Taysha Gene Therapies, Inc.
- Price
- $4.00 -39.8% · 6M
- Market Cap
- $1.30B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- IMCR is 1.2 times larger than TSHA by market capitalization ($1.55B against $1.30B).
- IMCR turns -4.2% of its revenue into net income, against -2728.0% for TSHA.
- IMCR carries 1.67 times debt per unit of equity, against 0.21 times for TSHA.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IMCR | TSHA |
|---|---|---|
| Market Cap | $1.55B | $1.30B |
| P/B Ratio | 3.68x | 3.37x |
| EPS | $-0.53 | $-0.38 |
| Book Value/Share | $8.15 | $1.19 |
| Revenue/Share | $8.36 | $0.02 |
| FCF/Share | $-0.80 | $-0.41 |
Profitability & Margins
| Metric | IMCR | TSHA |
|---|---|---|
| ROE | -4.3% | -38.6% |
| ROA | -1.6% | -31.8% |
| ROIC | -2.5% | -34.5% |
| Gross Margin | 99.0% | – |
| Operating Margin | -5.2% | -2792.3% |
| Net Margin | -4.2% | -2728.0% |
| EBT Margin | -0.6% | -2792.3% |
| Tax Rate | -561.6% | 0.0% |
Financial Health
| Metric | IMCR | TSHA |
|---|---|---|
| Current Ratio | 4.47x | 17.76x |
| Quick Ratio | 4.44x | – |
| D/E Ratio | 1.67x | 0.21x |
| Financial Leverage | 2.67x | 1.21x |
| Interest Coverage | -1.0x | -32.8x |
| Working Capital | $816M | $435M |
Cash Flow
| Metric | IMCR | TSHA |
|---|---|---|
| Operating Cash Flow | -$35M | -$132M |
| Free Cash Flow | -$41M | -$133M |
| Capital Spending | -$6M | -$380K |
| OCF Growth YoY | -204.1% | – |
| FCF Growth YoY | -244.7% | – |
| FCF/Sales | -9.6% | -2417.0% |
| CapEx/Sales | 1.4% | 7.0% |
Operational Efficiency
| Metric | IMCR | TSHA |
|---|---|---|
| Asset Turnover | 0.38x | 0.01x |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 33.5x | 2.3x |
| Days Inventory | 661 days | – |
| Payables Period | 2232 days | – |
Income Statement
| Metric | IMCR | TSHA |
|---|---|---|
| Total Revenue | $431M | $5M |
| Operating Income | -$23M | -$153M |
| Net Income | -$18M | -$150M |
| R&D Expense | $284M | $123M |
| SG&A Expense | $164M | – |
| Cost of Goods Sold | $4M | – |
Dividend & Shareholder Information
| Metric | IMCR | TSHA |
|---|---|---|
| Shares Outstanding | 52M | 326M |
IMCR vs TSHA: stock comparison and AI forecast
Which is bigger, IMCR or TSHA?
IMCR is 1.2 times larger than TSHA by market capitalization ($1.55B against $1.30B).
Which one does Intratio's AI model rank higher, IMCR or TSHA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.